Homepage Top Section2

The approval from the European Commission (EC) makes VYNDAQEL the first and only treatment for patients with ATTR-CM in the European Union (EU). Considered to be a rare,

The company will invest around $109m to develop the 135,000ft² gene therapy manufacturing facility. North Carolina Governor Roy Cooper said: “With our powerhouse research centres and highly-skilled workforce,

Beovu is claimed to be the first EC-approved anti-VEGF treatment to show better resolution of retinal fluid (IRF/SRF) against aflibercept. Wet AMD, a chronic and degenerative eye disease,

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers

Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restricting its interactions with both PD-1 and

The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major

The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous

The late-stage trial called PANORAMA, which features 402 patients, has been assessing Eylea in comparison to sham injection for the improvement of moderately severe to severe NPDR without

Based in Baarn, Covis is involved in the marketing and distribution of branded pharma products for the treatment of chronic and serious medical issues. The company supplies products